

MARRONE BIO INNOVATIONS INC

FORM 8-K (Current report filing)

Filed 10/04/16 for the Period Ending 10/03/16

Address	1540 DREW AVENUE DAVIS, CA 95618
Telephone	530-750-2800
CIK	0001441693
Symbol	MBII
SIC Code	2870 - Agricultural Chemicals
Industry	Agricultural Chemicals
Sector	Basic Materials
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): October 3, 2016

MARRONE BIO INNOVATIONS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36030
(Commission
File Number)

20-5137161
(I.R.S. Employer
Identification No.)

1540 Drew Avenue, Davis, CA
(Address of principal executive offices)

95618
(Zip Code)

Registrant's telephone number, including area code: (530) 750-2800

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events.

On October 3, 2016, Marrone Bio Innovations, Inc. (the "Company") was notified by The NASDAQ Stock Market LLC ("Nasdaq") that the Company has regained compliance with the applicable requirements for continued listing on The Nasdaq Capital Market and that the Hearings Panel has accordingly determined to continue listing the Company's common stock on The Nasdaq Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARRONE BIO INNOVATIONS, INC.

Dated: October 4, 2016

By: /s/ Linda V. Moore

Linda V. Moore

Senior Vice President, General Counsel and Secretary